Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

  • Technology appraisal guidance
  • TA171
  • Published: 
  • Last updated: 
Download guidance (PDF)

6 Recommendations for further research

6.1

The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.